Directing the biological activities of heparan sulfate oligosaccharides using a chemoenzymatic approach

Glycobiology

Volumn 22, Issue 1, 2012, Pages 96-106

  Xu, Yongmei ^a   Wang, Zhen ^b   Liu, Renpeng ^a   Bridges, Arlene S ^b   Huang, Xuefei ^c   Liu, Jian ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

antithrombin; FGF; heparan sulfate; oligosaccharides; sulfotransferases

Indexed keywords

ANTITHROMBIN; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE; HEPARIN; HEPTASACCHARIDE 2; HEPTASACCHARIDE 3; HEPTASACCHARIDE 4; IDURONIC ACID; NONASACCHARIDE 7; NONASACCHARIDE 8; NONASACCHARIDE 9; OLIGOSACCHARIDE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BINDING AFFINITY; CHEMOENZYMATIC SYNTHESIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME SYNTHESIS; EPIMERIZATION; FEASIBILITY STUDY; HYDROGENATION; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; ONE POT SYNTHESIS; PRIORITY JOURNAL; SAPONIFICATION; SULFATION;

ANTITHROMBINS; BIOCATALYSIS; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; FIBROBLAST GROWTH FACTOR 2; GLYCOSYLTRANSFERASES; HEPARITIN SULFATE; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RACEMASES AND EPIMERASES; SULFOTRANSFERASES; SULFURIC ACID ESTERS;

EID: 83255165450     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwr109     Document Type: Article

References (41)

1. Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi H, Kimata K. 2004. Characterization of the growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem. 279:12346-12354. (Pubitemid 38445801)
2. Ashikari-Hada S, Habuchi H, Sugaya N, Kobayashi T, Kimata K. 2009. Specific inhibition of FGF-2 signaling with 2-O-sulfated octasaccharides of heparin sulfate. Glycobiology. 19:644-654.
3. Atha DH, Lormeau J-C, Petitou M, Rosenberg RD, Choay J. 1985. Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry. 24:6723-6729. (Pubitemid 16207156)
4. Bai X, Esko JD. 1996. An animal cell mutant defective in heparan sulfate hexuronic acid 2-O-sulfation. J Biol Chem. 271:17711-17717. (Pubitemid 26250742)
5. Baleux F, Loureiro-Morais L, Hersant Y, Clayette P, Arenzana-Seisdedos F, Bonnaffe D, Lortat-Jacob H. 2009. A synthetic CD4-heparan sulfate glyco-conjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry. Nat Chem Biol. 5:743-748.
6. Borgenstrom M, Jalkanen M, Salmivirta M. 2003. Sulfated derivatives of Escherichia coli K5 polysaccharides as modulators of fibroblast growth factor signaling. J Biol Chem. 278:49882-49889. (Pubitemid 37548823)
7. Chen J, Avci FY, Muñoz EM, McDowell LM, Chen M, Pedersen LC, Zhang L, Linhardt RJ, Liu J. 2005. Enzymatically redesigning of biologically active heparan sulfate. J Biol Chem. 280:42817-42825. (Pubitemid 43049243)
8. Chen J, Jones CL, Liu J. 2007. Using an enzymatic combinatorial approach to identify anticoagulant heparan sulfate structures. Chem Biol. 14:986-993. (Pubitemid 47404901)
9. de Paz JL, Seeberger PH. 2008. Deciphering the glycosaminoglycan code with the help of microarrays. Mol Biosyst. 4:707-711. (Pubitemid 351871754)
10. Duncan MB, Liu M, Fox C, Liu J. 2006. Characterization of the N-deacetylase domain from the heparan sulfate N-deacetylase/N-sulfotransferase 2. Biochem Biophys Res Commun. 339:1232-1237. (Pubitemid 41790595)
11. Edavettal SC, Lee KA, Negishi M, Linhardt RJ, Liu J, Pedersen LC. 2004. Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1. J Biol Chem. 279:25789-25797. (Pubitemid 38756843)
12. Gama C, Tully SE, Sotogaku N, Clark PM, Rawat M, Vaidehi N, Goddard WA, Nishi A, Hsieh-Wilson LC. 2006. Sulfation patterns of glycosamino-glycans encode molecular recognition and activity. Nat Chem Biol. 2:467-473. (Pubitemid 44266308)
13. Guglieri S, Hricovini M, Raman R, Polito L, Torri G, Casu B, Sasisekharan R, Guerrini M. 2008. Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy. Biochemistry. 47:13862-13869.
14. Huang L, Huang X. 2007. Highly efficient synthesis of hyaluronic acid oligosaccharides. Chem Eur J. 13:529-540. (Pubitemid 46104700)
15. Huang X, Huang L, Wang H, Ye X-S. 2004. Iterative one-pot synthesis of oligosaccharides. Angew Chem Int Ed. 43:5221-5224. (Pubitemid 39382546)
16. Kakuta Y, Pedersen LG, Carter CW, Negishi M, Pedersen LC. 1997. Crystal structure of estrogen sulphotransferase. Nat Struct Biol. 4:904-908. (Pubitemid 27479440)
17. Kreuger J, Spillmann D, Li J-p, Lindahl U. 2006. Interactions between heparan sulfate and proteins: The concept of specificity. J Cell Biol. 174:323-327. (Pubitemid 44156762)
18. Lawrence R, Lu H, Rosenberg R, Esko JD, Zhang L. 2008. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods. 5:291-292. (Pubitemid 351455150)
19. Lee MK, Lander AD. 1991. Analysis affinity and structural selectivity in the binding of proteins to glycosaminoglycans: Development of a sensitive electrophoretic approach. Proc Natl Acad Sci USA. 88: 2768-2772. (Pubitemid 21916500)
20. Lee JC, Lu XA, Kulkarni SS, Wen YS, Hung SC. 2004. Synthesis of heparin oligosaccharides. J Am Chem Soc. 126:476-477. (Pubitemid 38084623)
21. Lindahl U, Li J, Kusche-Gullberg M, Salmivirta M, Alaranta S, Veromaa T, Emies J, Roberts I, Taylor C, Oreste P, et al. 2005. Generation of "neohe-parin" from E. Coli K5 capsular polysaccharide. J Med Chem. 48:349-352. (Pubitemid 40139778)
22. Liu J, Shworak NW, Sinaÿ P, Schwartz JJ, Zhang L, Fritze LMS, Rosenberg RD. 1999. Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J Biol Chem. 274:5185-5192.
23. Liu R, Xu Y Chen M, Weïwer M, Zhou X, Bridges AS, DeAngelis PL, Zhang Q, Linhardt RJ, Liu J. 2010. Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem. 285:34240-34249.
24. Maccarana M, Casu B, Lindahl U. 1993. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem. 268:23898-23905. (Pubitemid 23335364)
25. McCullough BJ, Kalapthakis JM, Chin W, Taylor K, Clarke DJ, Eastwood H, Campopiano D, MacMillan D, Dorin J, Barran PE. 2010. Binding a heparin derived disaccharide to defensin inspired peptides: Insights to antimicrobial inhibition from gas-phase measurements. Phys Chem Chem Phys. 12:3589-3596.
26. Peterson SP, Frick A, Liu J. 2009. Designing of biologically active heparan sulfate and heparin using an enzyme-based approach. Nat Prod Rep. 26:61-627.
27. Petitou M, van Boeckel CAA. 2004. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew Chem Int Ed. 43:3118-3133. (Pubitemid 39257600)
28. Raman R, Venkataraman G, Ernst S, Sasisekharan R. 2003. Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc Natl Acad Sci USA. 100:2357-2362. (Pubitemid 36297503)
29. Sheng Z, Liu R, Xu Y, Liu J. 2011. The dominating role of N-deacetylase/N-sulfotransferase 1 in forming domain structures in heparan sulfate. J Biol Chem. 286:19768-19776.
30. Shriver Z, Raguram S, Sasisekharan R. 2004. Glycomics: A pathway to a class of new and improved therapeutics. Nat Rev Drug Discov. 3:863-873. (Pubitemid 39405947)
31. Sundaram M, Qi Y, Shriver Z, Liu D, Zhao G, Venkataraman G, Langer R, Sasisekharan R. 2003. Rational design of low-molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci USA. 100:651-656. (Pubitemid 36126107)
32. Venkataraman G, Shriver Z, Raman R, Sasisekharan R. 1999. Sequencing complex polysaccharides. Science. 286:537-542.
33. Wang Z, Xu Y, Yang B, Tiruchinapally G, Sun B, Liu R, Dulaney S, Liu J, Huang X. 2010. Preactivation-based one-pot combinatorial synthesis of heparin-like hexasaccharides for the analysis of heparin-protein interactions. Chem Eur J. 16:8365-8375.
34. Wei W, Ninonuevo MR, Sharma A, Dana-Leon LM, Leary JA. 2011. A comprehensive compositional analysis of heparin/heparan sulfate-derived disac-charides from human serum. Anal Chem. 83:3703-3708.
35. Xia G, Chen J, Tiwari V, Ju W, Li J-P, Malmström A, Shukla D, Liu J. 2002. Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1. J Biol Chem. 277:37912-37919.
36. Xu Y, Masuko S, Takieddin M, Xu H, Liu R, Jing J, Mousa SA, Linhardt RJ, Liu J. 2011. Chemoenzymatic synthesis of homogeneous ultra-low molecular weight heparin. Science. in press.
37. Xu D, Moon A, Song D, Pedersen LC, Liu J. 2008. Engineering sulfotrans-ferases to modify heparan sulfate. Nat Chem Biol. 4:200-202. (Pubitemid 351264127)
38. Yamada S, Yoshida K, Sugiura M, Sugahara K, Khoo KH, Morris HR, Dell A. 1993. Structural studies on the bacterial lyase-resistant tetrasaccharides derived from the antithrombin III-binding site of porcine intestinal heparin. J Biol Chem. 268:4780-4787. (Pubitemid 23081594)
39. Zaia J, Costello CE. 2001. Compositional analysis of glycosaminoglycans by electrospray mass spectrometry. Anal Chem. 73:233-239. (Pubitemid 32061834)
40. Zhang Z, McCallum SA, Xie J, Nieto L, Corzana F, Jiménez-Barbero J, Chen M, Liu J, Linhardt RJ. 2008. Solution structure of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc. 130:12998-13007.
41. Zhang L, Yoshida K, Liu J, Rosenberg RD. 1999. Anticoagulant heparan sulfate precursor structures in F9 embryonic carcinoma cells. J Biol Chem. 274:5681-5691. (Pubitemid 29109221)